Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Revolution Medicines, Inc. (NASDAQ: RVMD) Q3 2024 Earnings Call Transcript November 6, 2024 Revolution Medicines, Inc. misses on earnings expectations. Reported EPS is $-0.94 EPS, expectations were ...

The highest priority has been to advance RMC-6236, our first-in-class RAS(ON) multi-selective inhibitor, into its first pivotal trials, one in pancreatic ... lung cancer, including both ...

Beyond Pancreatic Cancer: The company is currently evaluating its clinical-stage RAS(ON) inhibitors as monotherapy and ... study evaluating RMC-6236 with pembrolizumab in the fourth quarter ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and ...

IL-13Rα2 expression is associated with poor clinical outcome in multiple tumor types including prostate cancer ... as both monotherapy and in combination with pembrolizumab.

The dose expansion part of TROPION-PanTumor01 is enrolling several different cohorts including patients with NSCLC, triple-negative breast cancer (TNBC), HR-positive, HER2-low or negative breast ...

The Phase 1/2 multi-centre, open-label trial has been designed to assess NDI-101150 as a monotherapy (50-200 mg dose) and in combination with 200 mg pembrolizumab in the treatment of adults with ...